Hypertrophic Scar Clinical Trial
Official title:
Effects of Pulsed Dye and CO2 Laser in Treatment of Hypertrophic Burn Scars.
NCT number | NCT04769089 |
Other study ID # | M-10590 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | December 19, 2017 |
Est. completion date | June 24, 2020 |
Verified date | February 2021 |
Source | The Metis Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A prospective, double blind, randomized controlled human clinical trial will be conducted by enrolling patients referred for laser treatment from the USAISR burn clinic. Laser candidates will be asked to participate who have an area of extremity or truncal scar measuring approximately 6cmX6cm total, in one contiguous region. The study sites, will consist of four equally sized treatment areas (3cm x 3cm), will be randomized to be treated with PDL, CO2, a combination of CO2+PDL, and an untreated control for 6 treatments. The areas will be photographed prior to each treatment and at the final visit 4-6 months after the last treatment. Color, pliability and thickness will be measured using a colorimeter, cutometer and high frequency ultrasound respectively at each appointment. Additionally, the Patient Observer Scar Assessment Scale (POSAS) will be used to score the quality of the scar, using two trained, blinded observers. The patients will also be asked on a voluntary basis for a pre-trial and post-trial 3mm punch biopsy to evaluate for the presence of histological changes.
Status | Completed |
Enrollment | 25 |
Est. completion date | June 24, 2020 |
Est. primary completion date | June 24, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Must have at least four areas of burn scar located on the trunk or extremities measuring 3cm x 3cm and not previously treated with laser. 2. Timing: There has been a minimum of 1 month after burn closure 3. The subject is at least 18 years of age and not older than 65. 4. Able and willing to provide verbal and written consent. Exclusion Criteria: 1. Active infection in experimental area 2. Use of isotretinoin (Accutane) in last six months 3. Life or limb-threatening injury/disease 4. Prior history of non-compliance with medical regimes 5. Active drug use/abuse 6. Active psychiatric illness except depression (unless being treated for suicidal intentions) 7. Pregnancy 8. Active cancer, or new diagnosis of cancer within the past 5 years, with the exception of basal cell carcinoma, melanoma and squamous cell carcinoma, as long as the subject is disease free at the time of enrollment. 9. Prior PDL or other laser treatment of the study area. 10. Patient unable to tolerate laser procedure. |
Country | Name | City | State |
---|---|---|---|
United States | United States Army Institute of Surgical Research | Fort Sam Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The Metis Foundation | United States Army Institute of Surgical Research |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effectiveness of laser treatments | Using the Patient and Observer Scar Assessment Scale (POSAS), evaluate the effectiveness of Pulse Dye Laser (PDL) and Carbon Dioxide (CO2) laser treatment on symptoms related to Hypertrophic Burn Scar (HBS) | 4-6 weeks post treatment | |
Secondary | Improvement of symptoms | To longitudinally compare the change in symptoms by treatment modality between treatment sessions by assessment with the Patient and Observer Scar Assessment Scale (POSAS) measured for each patient and two observers (to increase score reliability) at each follow-up visit. | 4-6 weeks post treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03376620 -
Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients
|
Phase 3 | |
Terminated |
NCT03935594 -
Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars
|
Phase 2 | |
Recruiting |
NCT03561376 -
Zinc Oxide Versus Petrolatum Following Skin Surgery
|
Early Phase 1 | |
Recruiting |
NCT06033430 -
Effectiveness of Dry Needling in Linear Scar Tissue
|
N/A | |
Recruiting |
NCT03631368 -
Treatment of Hypertrophic Scars With Intradermal Botox
|
Phase 2 | |
Completed |
NCT03630198 -
Pain Outcomes Following Intralesional Corticosteroid Injections
|
Phase 4 | |
Recruiting |
NCT02168634 -
The Use of Botulinum Toxin in the Treatment of Itching From Hypertrophic Scar -- A Randomised Controlled Trial
|
N/A | |
Completed |
NCT02030275 -
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults
|
Phase 2 | |
Recruiting |
NCT04506255 -
Silicone Taping for the Improvement of Abdominal Donor Site Scars
|
N/A | |
Not yet recruiting |
NCT04593706 -
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars)
|
N/A | |
Completed |
NCT04643223 -
Effect of Elastic Bandage With Tension on the Inflammatory Response of Hypertrophic Scars
|
N/A | |
Completed |
NCT03986346 -
The Vascularity Changes of Scars With Laser Therapy
|
N/A | |
Completed |
NCT04619589 -
Characterization of Dyschromic Hypertrophic Scar
|
||
Completed |
NCT06347081 -
Effect of Nd-YAG Laser on Hypertrophic Scar
|
N/A | |
Completed |
NCT05412745 -
Class I Medical Device on Post-surgical Scars
|
N/A | |
Terminated |
NCT03403621 -
Hypertrophic Scar Prevention by Novel Topical Gel Application
|
Phase 1/Phase 2 | |
Completed |
NCT00754247 -
A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars
|
Phase 4 | |
Recruiting |
NCT03692273 -
Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar
|
N/A | |
Completed |
NCT03795116 -
Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention
|
Phase 2 | |
Not yet recruiting |
NCT03850119 -
Nanofat on Wound Healing and Scar Formation
|
N/A |